Navidea Biopharmaceuticals enrolls first patient in cervical cancer study of Lymphoseek®
Navidea announced the first patient has been enrolled in a clinical study evaluating Lymphoseek® (technetium Tc 99m tilmanocept) injection in women with known cervical cancer. The study, funded by a Fast-track grant from the NIH will assess use of Lymphoseek in SLNB during cervical cancer surgery. February 11, 2016